Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00454909 · ClinicalTrials.gov registry record · Phase 2
Immunogenicity and Safety of Meningococcal Vaccine GSK134612 vs. Menactra® in Healthy Adolescent/Adults Aged 10-25 Years.
A Phase 2 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 2
- Development phase
- 873
- Enrollment target
NCT00454909 is a Phase 2 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 873 participants.
The verdict
NCT00454909, a Phase 2 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 873 participants
- Enrollment target
Study Summary
The purpose of the study is to characterize the safety and immunogenicity of 1 dose of GSK Biologicals' meningococcal vaccine GSK134612 as compared to Menactra® in adolescents/adults 11-25 years of age. The Protocol Posting has been updated in order to comply with the FDA Amendment Act, Sep 2007. The protocol posting has been updated following a protocol amendment.
Interventions
- BIOLOGICAL Menactra®
- BIOLOGICAL Meningococcal vaccine 134612
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 873 participants |
| Start Date | 2007-04-23 |
| Est. Completion | 2008-04-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00454909
The ClinicalTrials.gov registry entry for NCT00454909 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 873 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Menactra® is the first listed.
NCT00454909 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00454909 about?
NCT00454909 is a clinical study titled "Immunogenicity and Safety of Meningococcal Vaccine GSK134612 vs. Menactra® in Healthy Adolescent/Adults Aged 10-25 Years.". The purpose of the study is to characterize the safety and immunogenicity of 1 dose of GSK Biologicals' meningococcal vaccine GSK134612 as compared to Menactra® in adolescents/adults 11-25 years of age. The Protocol Posting has been updated in order to comply with the FDA Amendment Act, Sep 2007. ...
What is the current status of trial NCT00454909?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 873 participants. The study started on 2007-04-23. Estimated completion is 2008-04-11.
What interventions are being tested in trial NCT00454909?
The interventions under investigation include: Menactra® (BIOLOGICAL), Meningococcal vaccine 134612 (BIOLOGICAL).
Who is sponsoring clinical trial NCT00454909?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.